THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

March 21, 2024
Merck to invest 300m euros in new bioprocessing center in Korea

German pharmaceutical group Merck Life Science said Thursday the company will invest around 300 million euros ($326 million) to build a new bioprocessing complex in South Korea, its largest investment yet in the Asia-Pacific region. The new investment comes as the company renews its commitment to ...
March 21, 2024
SK Bioscience exports cell-cultured flu vaccines to Thailand

South Korean pharmaceuticals firm SK Bioscience said Thursday that it exported its cell-cultured flu vaccine, SKYCellflu, to Thailand, marking its first entry into a market with southern hemisphere requirements. The company shipped out approximately 440,000 doses of SKYCellflu to its Thai partner ...
March 21, 2024
SK bioscience exports influenza vaccine SKYCellflu to Thailand

SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, said Thursday the company has exported its influenza vaccine to Thailand as part of efforts to expand its business presence in the southeast Asian market. The company has shipped around 440,000 doses of SKYCellflu, a cell-cult...
March 21, 2024
Global pharma Merck to build new bioprocessing production facility in S. Korea

Global pharmaceutical company Merck Life Science said Thursday it will invest some 430 billion won ($324 million) to build a new bioprocessing production facility in South Korea. The European bio firm plans to build a 43,000 square-meter center in Daejeon, about 140 kilometers south of Seoul, equi...
March 19, 2024
Drugmakers feeling pinch from doctors’ walkout

The ongoing tug-of-war between the South Korean government and medical professionals over the proposed increase in the number of medical students could have negative impacts on local drug companies’ revenues as well, industry sources said Tuesday. According to officials from local pharmaceutical ...
March 18, 2024
Celltrion's Zymfentra makes US debut

Korean biopharmaceuticals firm Celltrion announced Monday that its new autoimmune disease treatment Zymfentra has been launched in the US market. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab Remsima. In October last year, the US Food and Drug Administration approved ...
March 18, 2024
Celltrion's new autoimmune disease treatment Zymfentra hits US market

South Korean biopharmaceutical firm Celltrion said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the US market. Zymfentra, a subcutaneous injection formulation of Celltrion's infliximab Remsima, won approval from the US Food and Drug Administration last year for use o...
March 18, 2024
Yuhan restores chairperson post after 28 years

South Korean pharmaceutical giant Yuhan has decided to reinstate the chairperson and vice chairperson positions for the first time in 28 years, since Chairman Yeon Man-hee stepped down from his post in 1996. Yuhan shareholders approved changes to the articles of incorporation to reestablish the po...
March 13, 2024
Samsung Biologics on smooth ride for record orders

Samsung Biologics is off to a promising start this year with two large-scale contract manufacturing deal signings in March alone. According to Samsung Biologics on Wednesday, the company recently inked a contract manufacturing deal with MSD Switzerland, worth some $71 million. The deal, set to exp...
March 13, 2024
LuluMedic, India’s SVA Solutions team up on insurance plans for overseas workers

South Korean health care tech company LuluMedic said Tuesday that it has partnered with Indian consulting firm SVA Solutions to promote its comprehensive insurance plans tailored for overseas workers. This initiative aims to meet the increasing demand from Korean companies to comply with the Serio...
February 29, 2024
CHA Biotech shatters records with 954 billion won revenue

CHA Biotech announced on Thursday that it achieved a historic milestone in its annual revenue for last year, marking a record-breaking consolidated revenue of 954 billion won ($715 million), a notable 13 percent increase from the previous year. The company also saw a significant improvement in ope...
February 29, 2024
Celltrion begins shipment of Remsima SC for US debut

Celltrion`s autoimmune disease treatment Zymfentra (Celltrion) Biopharmaceutical giant Celltrion announced Wednesday that the first batch of its new autoimmune disease treatment Zymfentra, also known as Remsima SC, has been shipped for its planned debut in the US next month. Zymfentra is the firs...
February 27, 2024
Merck’s Keytruda tops drug sales in Korea

Merck’s immuno-oncology drug Keytruda, one of the best-selling drugs in the world, topped drug sales in Korea for the second consecutive year in 2023, according to market tracker IQVIA on Tuesday. Keytruda’s sales in Korea came to some 399 billion won ($300 million) in 2023, up 159 billion won f...
February 23, 2024
Kolmar Korea finds anti-aging microorganism

Kolmar Korea, a cosmetics original design manufacturer, said Thursday it has found a microbiome that can slow down skin aging induced by sun exposure for the first time, which could be a breakthrough innovation in the anti-aging skincare industry. Photoaging refers to the characteristic changes to...
February 19, 2024
Samsung Bioepis posts record-high biosimilar sales

Overseas biosimilar sales of Samsung Bioepis, a biosimilar developer under Samsung Group, reached an all-time high in 2023, according to its partner companies on Sunday. According to Samsung Bioepis’ US partners, Biogen and Organon, sales of Samsung Bioepis’ biosimilar products in overseas marke...

1 2 3 4 5 6

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099